{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:11:01Z","timestamp":1774487461026,"version":"3.50.1"},"reference-count":36,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Eukaryot Gene Expr"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>Long non-coding RNAs (lncRNAs) are intensively involved in the pathogenesis of multiple myeloma (MM). The purpose of this study was to investigate the potentials of DUBR in MM. Gene expression was determined using RT-qPCR and western blot. The release of ROS, MDA, ferrous iron, and GSH was detected with corresponding assays. Cell behavior was detected using CCK-8, colony formation, transwell, and PI staining assays. The binding sites between miR-17-3p and DUBR\/TFRC was verified firmed by RIP, RNA pull-down, as well as luciferase assays. We found that low levels of DUBR predicted poor prognosis of MM patients. However, overexpressed DUBR enhanced the chemosensitivity of MM cells to bortezomib (BTZ), as well as promoted the ferroptosis of MM cells. DUBR sponged miR-17-3p to upregulate TFRC. However, TFRC knockdown abrogated the effects of overexpressed DUBR and promoted the aggressiveness of MM cells. In summary, DUBR promotes the chemosensitivity of MM cells to BTZ via regulating miR-17-3p\/TFRC axis. Therefore, targeting DUBR may be a potential target for MM.\n<\/p>","DOI":"10.1615\/critreveukaryotgeneexpr.2024056835","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T21:08:52Z","timestamp":1736197732000},"page":"51-62","source":"Crossref","is-referenced-by-count":3,"title":["DUBR\/miR-17-3p\/TFRC\/HO-1 Axis Promotes the Chemosensitivity of Multiple Myeloma"],"prefix":"10.1615","volume":"35","author":[{"given":"Tao","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meihua","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.","DOI":"10.1016\/j.ctrv.2021.102284"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Gallo Cantafio ME, Torcasio R, Scionti F, Mesuraca M, Ronchetti D, Pistoni M, Bellizzi D, Passarino G, Morelli E, Neri A, Viglietto G, Amodio N. GPER1 activation exerts anti-tumor activity in multiple myeloma. Cells. 2023;12(18):2226.","DOI":"10.3390\/cells12182226"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802-24.","DOI":"10.1002\/ajh.27422"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Blade J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosinol L, Usmani SZ, Zamagni E, Richardson P. Extramedullary disease in multiple myeloma: A systematic literature review. Blood Cancer J. 2022;12(3):45.","DOI":"10.1038\/s41408-022-00643-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660-75.","DOI":"10.1182\/blood-2018-09-825331"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73(3):275-85.","DOI":"10.3322\/caac.21771"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Nemeth K, Bayraktar R, Ferracin M, Calin GA. Non-coding RNAs in disease: From mechanisms to therapeutics. Nat Rev Genet. 2024;25(3):211-32.","DOI":"10.1038\/s41576-023-00662-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Venkatesh J, Wasson MD, Brown JM, Fernando W, Marcato P. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. Cancer Lett. 2021;509:81-8.","DOI":"10.1016\/j.canlet.2021.04.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Zhao P, Zhao X. Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients. J Clin Lab Anal. 2021;35(11):e23924.","DOI":"10.1002\/jcla.23924"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Ren Y, Liu Y, He W, Zhao W, Pan J, Gao H, Li Y, Zhang Y, Wang W. Expression of NEAT1 can be used as a predictor for Dex resistance in multiple myeloma patients. BMC Cancer. 2023;23(1):630.","DOI":"10.1186\/s12885-023-11084-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Zang X, Wang J, Xia Y, Li J, Chen L, Gu Y, Shen X. LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma. Leuk Res. 2022;123:106967.","DOI":"10.1016\/j.leukres.2022.106967"},{"key":"13","doi-asserted-by":"crossref","unstructured":"He Q, Chen N, Wang X, Li P, Liu L, Rong Z, Liu W, Jiang K, Zhao J. Prognostic value and immunological roles of GPX3 in gastric cancer. Int J Med Sci. 2023;20(11):1399-416.","DOI":"10.7150\/ijms.85253"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Liu S, Bu X, Kan A, Luo L, Xu Y, Chen H, Lin X, Lai Z, Wen D, Huang L, Shi M. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett. 2022;528:16-30.","DOI":"10.1016\/j.canlet.2021.12.026"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Nie W, Hu MJ, Zhang Q, Lu J, Qian FF, Zhang LL, Hu F, Li CH, Cao SH, Li JW, Wang Y, Zhang XY, Xu MD, Han BH. DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation. Acta Pharmacol Sin. 2022;43(1):157-66.","DOI":"10.1038\/s41401-021-00624-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: The role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18(5):280-96.","DOI":"10.1038\/s41571-020-00462-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Zhang Y, He F, Hu W, Sun J, Zhao H, Cheng Y, Tang Z, He J, Wang X, Liu T, Luo C, Lu Z, Xiang M, Liao Y, Wang Y, Li J, Xia J. Bortezomib elevates intracellular free Fe(2+) by enhancing NCOA4-mediated ferritinophagy and synergizes with RSL-3 to inhibit multiple myeloma cells. Ann Hematol. 2024;103(9):3627-37.","DOI":"10.1007\/s00277-024-05762-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Li W, Fu H, Fang L, Chai H, Ding B, Qian S. Andrographolide induced ferroptosis in multiple myeloma cells by regulating the P38\/Nrf2\/HO-1 pathway. Arch Biochem Biophys. 2023;742:109622.","DOI":"10.1016\/j.abb.2023.109622"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Gao D, Liu R, Lv Y, Feng Y, Hong F, Xu X, Hu J, He A, Yang Y. A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma. Front Oncol. 2023;13:999688.","DOI":"10.3389\/fonc.2023.999688"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Lu Y, Yang Q, Su Y, Ji Y, Li G, Yang X, Xu L, Lu Z, Dong J, Wu Y, Bei JX, Pan C, Gu X, Li B. MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma. Cell Death Dis. 2021;12(6):511.","DOI":"10.1038\/s41419-021-03790-w"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gulla A, Gallo Cantafio ME, Misso G, Tagliaferri P, Tassone P, Caraglia M, De Rosa G. Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int. 2014;2014:217365.","DOI":"10.1155\/2014\/217365"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Jin Y, Li J, Tang C, He K, Shan D, Yan S, Deng G. A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer. Medicine. 2023;102(18):e33664.","DOI":"10.1097\/MD.0000000000033664"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Zhong X, Tao Y, Chang J, Zhang Y, Zhang H, Wang L, Liu Y. Prognostic signature of immune genes and immune-related LncRNAs in neuroblastoma: A study based on geo and target datasets. Front Oncol. 2021;11:631546.","DOI":"10.3389\/fonc.2021.631546"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Karthikeyan SK, Xu N, Ferguson 3rd JE, Rais-Bahrami S, Qin ZS, Manne U, Netto GJ, S. Chandrashekar D, Varambally S. Identification of androgen response-related lncRNAs in prostate cancer. Prostate. 2023;83(6): 590-601.","DOI":"10.1002\/pros.24494"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Chen L, Wei K, Li J, Li Y, Cao H, Zheng Z. Integrated analysis of LncRNA-mediated ceRNA network in calcific aortic valve disease. Cells. 2022;11(14):2204.","DOI":"10.3390\/cells11142204"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Zhao Y, Zhang H, Cui JG, Wang JX, Chen MS, Wang HR, Li XN, Li JL. Ferroptosis is critical for phthalates driving the blood-testis barrier dysfunction via targeting transferrin receptor. Redox Biol. 2023;59:102584.","DOI":"10.1016\/j.redox.2022.102584"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and management of multiple myeloma: A review. JAMA. 2022;327(5):464-77.","DOI":"10.1001\/jama.2022.0003"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Ismail NH, Mussa A, Al-Khreisat MJ, Mohamed Yusoff S, Husin A, Al-Jamal HAN, Johan MF, Islam MA. Dysregulation of non-coding RNAs: Roles of miRNAs and lncRNAs in the pathogenesis of multiple myeloma. Noncoding RNA. 2023;9(6):68.","DOI":"10.3390\/ncrna9060068"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Zhao Z, Sun W, Guo Z, Zhang J, Yu H, Liu B. Mechanisms of lncRNA\/microRNA interactions in angiogenesis. Life Sci. 2020;254:116900.","DOI":"10.1016\/j.lfs.2019.116900"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Yang X, Huang H, Wang X, Liu H, Liu H, Lin Z. Knockdown of lncRNA SNHG16 suppresses multiple myeloma cell proliferation by sponging miR-342-3p. Cancer Cell Int. 2020;20:38.","DOI":"10.1186\/s12935-020-1118-1"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Liu Q, Ran R, Song M, Li X, Wu Z, Dai G, Xia R. LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt\/beta-catenin\/cyclin D1 signaling via PLAGL2. Cell Biol Toxicol. 2022;38(6):979-93.","DOI":"10.1007\/s10565-021-09628-7"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Faltejskova P, Bocanek O, Sachlova M, Svoboda M, Kiss I, Vyzula R, Slaby O. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012;12(4):199-204.","DOI":"10.3233\/CBM-130308"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Xiang P, Yeung YT, Wang J, Wu Q, Du R, Huang C, Jia X, Gao Y, Zhi Y, Guo F, Wei H, Zhang D, Liu Y, Liu L, Liang L, Wang J, Song Y, Liu K, Fang B. miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. Int J Cancer. 2021;148(12):3071-85.","DOI":"10.1002\/ijc.33528"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401-21.","DOI":"10.1016\/j.cell.2022.06.003"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Yu Y, Yan Y, Niu F, Wang Y, Chen X, Su G, Liu Y, Zhao X, Qian L, Liu P, Xiong Y. Ferroptosis: A cell death connecting oxidative stress, inflammation and cardiovascular diseases. Cell Death Discov. 2021;7(1):193.","DOI":"10.1038\/s41420-021-00579-w"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Huang L, Feng J, Zhu J, Yang J, Xiong W, Lu X, Chen S, Yang S, Li Y, Xu Y, Shen Z. A strategy of Fenton reaction cycloacceleration for high-performance ferroptosis therapy initiated by tumor microenvironment remodeling. Adv Healthc Mater. 2023;12(18):e2203362.","DOI":"10.1002\/adhm.202203362"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zheng J, Conrad M. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32(6):920-37.","DOI":"10.1016\/j.cmet.2020.10.011"}],"container-title":["Critical Reviews in Eukaryotic Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/7fe059f61461fe44\/CRE-56835.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:34:31Z","timestamp":1740468871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/6dbf508d3b17c437,071f340523ff35b4,7fe059f61461fe44.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/critreveukaryotgeneexpr.2024056835","relation":{},"ISSN":["1045-4403"],"issn-type":[{"value":"1045-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}